HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
GILD
Gilead Sciences Inc
Healthcare Drug Manufacturers - General · California, USA · Reports in usd
Market Cap: $159.03B
Market Cap
$159.03B
Enterprise Val
$173.56B
P/E Ratio
17.26
P/B Ratio
6.76
Trailing PEG (1Y)
0.32
As Of
Jun 7, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$23.43B
Gross Margin79.24%
Profit Margin79.24%
Return on Equity42.16%
Return on Assets16.06%
Current Ratio1.97
Debt/Equity0.94
LT Debt/Equity0.89
Revenue Per Share5.61

Income Statement

Mar 31, 2026
Revenue$6.96B
Cost of Revenue$1.45B
Gross Profit$5.52B
R&D$1.37B
SG&A$1.45B
Operating Expenses$2.93B
Operating Income$2.59B
Interest Expense$240.0M
Tax Expense$559.0M
Net Income$2.02B
EPS (Basic)$1.63
EPS (Diluted)$1.61
EBIT$2.82B
EBITDA$3.51B
Consolidated Income$2.02B
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$7.63B
Accounts Receivable$4.74B
Inventory$1.91B
Current Assets$18.64B
LT Investments$983.0M
Property, Plant & Equipment$5.64B
Intangibles$24.70B
Non-Current Assets$37.64B
Total Assets$56.28B
Accounts Payable$645.0M
Current Debt$1.31B
Current Liabilities$9.48B
LT Debt$20.86B
Non-Current Liabilities$23.37B
Total Liabilities$32.85B
Total Debt$22.17B
Retained Earnings$14.13B
Shareholder Equity$23.52B
Shares Outstanding1,241,420,528

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow$2.54B
Investing Cash Flow$1.77B
Financing Cash Flow-$4.24B
CapEx-$117.0M
Free Cash Flow$2.43B
Depreciation & Amort.$689.0M
Stock-Based Comp$218.0M
Acquisitions / Disposals-$109.0M
Investment Activity$2.01B
Debt Issued/Repaid-$2.77B
Equity Issued/Repaid-$253.0M
Dividends Paid-$1.04B
Net Change in Cash$65.0M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h